| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Dr. Hellerstedt is Fellow, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI.
Dr. Pienta is Professor, Internal Medicine and Urology and Director, Urologic Oncology Program, University of Michigan Medical Center, Ann Arbor, MI.
Androgen deprivation therapy remains a mainstay of treatment for men with prostate cancer. New uses for hormonal therapy, including use in the adjuvant and neoadjuvant setting, are being evaluated. Prevention of the side effects of therapy has led to the development of alternative schedules and therapeutics.
This article has been cited by other articles:
|
|
 |
|
  G. Attard, A. H.M. Reid, T. A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd, et al. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven J. Clin. Oncol., October 1, 2008; 26(28): 4563 - 4571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schayowitz, G. Sabnis, V. C.O. Njar, and A. M.H. Brodie Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro Mol. Cancer Ther., January 1, 2008; 7(1): 121 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A Clay, S. Perera, J. M Wagner, M. E Miller, J. B Nelson, and S. L Greenspan Physical Function in Men With Prostate Cancer on Androgen Deprivation Therapy Physical Therapy, October 1, 2007; 87(10): 1325 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yang, Y.-J. Chang, H. Miyamoto, S. Yeh, J. L. Yao, P. A. di Sant'Agnese, M.-Y. Tsai, and C. Chang Suppression of Androgen Receptor Transactivation and Prostate Cancer Cell Growth by Heterogeneous Nuclear Ribonucleoprotein A1 via Interaction with Androgen Receptor Coregulator ARA54 Endocrinology, March 1, 2007; 148(3): 1340 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yang, Y.-J. Chang, H. Miyamoto, J. Ni, Y. Niu, Z. Chen, Y.-L. Chen, J. L. Yao, P. A. di Sant'Agnese, and C. Chang Transgelin Functions as a Suppressor via Inhibition of ARA54-Enhanced Androgen Receptor Transactivation and Prostate Cancer Cell Growth Mol. Endocrinol., February 1, 2007; 21(2): 343 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. de Bono, J. Bellmunt, G. Attard, J. P. Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, et al. Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer J. Clin. Oncol., January 20, 2007; 25(3): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Swami, A. V. Krishnan, J. Moreno, R. B. Bhattacharyya, D. M. Peehl, and D. Feldman Calcitriol and Genistein Actions to Inhibit the Prostaglandin Pathway: Potential Combination Therapy to Treat Prostate Cancer J. Nutr., January 1, 2007; 137(1): 205S - 210S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Peng, P. J. Malloy, J. Wang, and D. Feldman Growth Inhibitory Concentrations of Androgens Up-Regulate Insulin-Like Growth Factor Binding Protein-3 Expression via an Androgen Response Element in LNCaP Human Prostate Cancer Cells Endocrinology, October 1, 2006; 147(10): 4599 - 4607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gao, X. Ouyang, W. A. Banach-Petrosky, W. L. Gerald, M. M. Shen, and C. Abate-Shen Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer PNAS, September 26, 2006; 103(39): 14477 - 14482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Husbeck, R. S. Bhattacharyya, D. Feldman, and S. J. Knox Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol. Cancer Ther., August 1, 2006; 5(8): 2078 - 2085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Pienta and D. C. Smith Advances in Prostate Cancer Chemotherapy: A New Era Begins CA Cancer J Clin, September 1, 2005; 55(5): 300 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nagpal, S. Na, and R. Rathnachalam Noncalcemic Actions of Vitamin D Receptor Ligands Endocr. Rev., August 1, 2005; 26(5): 662 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jaggi, P. S. Rao, D. J. Smith, M. J. Wheelock, K. R. Johnson, G. P. Hemstreet, and K.C. Balaji E-Cadherin Phosphorylation by Protein Kinase D1/Protein Kinase C{micro} is Associated with Altered Cellular Aggregation and Motility in Prostate Cancer Cancer Res., January 15, 2005; 65(2): 483 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Stangelberger, A. V. Schally, J. L. Varga, M. Zarandi, K. Szepeshazi, P. Armatis, and G. Halmos Inhibitory Effect of Antagonists of Bombesin and Growth Hormone-Releasing Hormone on Orthotopic and Intraosseous Growth and Invasiveness of PC-3 Human Prostate Cancer in Nude Mice Clin. Cancer Res., January 1, 2005; 11(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Jia, C. S-Y. Choong, C. Ricciardelli, J. Kim, W. D. Tilley, and G. A Coetzee Androgen Receptor Signaling: Mechanism of Interleukin-6 Inhibition Cancer Res., April 1, 2004; 64(7): 2619 - 2626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Miyamoto, P. Marwah, A. Marwah, H. Lardy, and C. Chang 3beta -Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity PNAS, April 15, 2003; 100(8): 4440 - 4444. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
